Merck KGaA Keen To Remain Key Player In MS Now And In Future
Executive Summary
The German company is predicting sales in mid-triple-digits in 2019 for Mavenclad, its multiple sclerosis drug which has just been launched in the US, and has highlighted more promising MS data for its BTK inhibitor evobrutinib.
You may also be interested in...
Merck KGaA Rebounds After COVID-19 Lockdowns
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.
Merck KGaA Sees Coronavirus Impact Subsiding In Q2
The German company is exposed to events in China across its three divisions - healthcare, life sciences and performance materials - but says that COVID-19 should only affect 2020 sales by 1%, unless a global recession happens.
Novartis Upbeat As Ofatumumab Data Delivers In MS
Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.